^
Association details:
| Biomarker: | BRCA2 deletion + RB1 deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug Class: | PARP inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
BRCA2-RB1 co-loss and ADT resistance in aggressive prostate cancer.
Published date:
05/16/2018
Excerpt:
...we showed that PARPi or platinum in combination with a pan-Wnk inhibitor significantly abrogated BRCA2-RB1 null LNCaP growth in vitro rather than the Wnk inhibitor or PARPi/platinum treatment alone.
